According to the findings of a systematic review, Zavegepant nasal spray is beneficial to provide pain relief and alleviate other bothersome symptoms of migraine. Investigators aimed to evaluate the effectiveness and safety of Zavegepant nasal spray for managing acute migraine attacks while also identifying any potential adverse events. The study encompassed adult subjects having acute migraines who were treated with Zavegepant nasal spray in either non-randomized controlled trials (RCTs) or RCTs.

To gather relevant data, a thorough search was conducted in various databases like PubMed, Embase, Cochrane Library, and ClinicalTrials.gov, using specific keywords such as "calcitonin gene-related peptide receptor antagonist", "migraine," and "Zavegepant nasal spray".  A narrative synthesis approach was employed to summarize and assess the extracted data from the incorporated trials, with a primary focus on assessing the safety and effectiveness of Zavegepant nasal spray for the management of acute migraine.

The study incorporated 3 clinical trials, comprising 1 open-label trial and 2 RCTs. In total, 3681 volunteers were involved in these phase 2/3 trials. The criteria for inclusion were formulated to cover individuals who had a background of migraines, whether accompanied by aura or not, enduring for over a year, in accordance with the guidelines outlined in the third edition of the International Classification of Headache Disorders. Tabulation and discussion of the findings from the trials were done.

The studies analyzed in this assessment established the efficacy of Zavegepant in offering pain alleviation and relief from the most troublesome symptoms for individuals with a migraine history, particularly at doses of 10 mg and 20 mg. The reported adverse events linked to Zavegepant were primarily of mild or moderate intensity, indicating favorable tolerability. Thus, the nasal spray formulation of Zavegepant holds promise as a valuable addition to the existing treatment protocols for managing acute migraine episodes. 

However, further research is required to validate its effectiveness and safety, determine the optimal dosage and administration methods, and assess its efficacy in diverse populations. Additionally, investigating its long-term impact on migraine burden, patient satisfaction, and cost-effectiveness would be crucial aspects to explore.